American Psychological Association

NPAC Responded to American Psychological Associations’ call for comments on its proposed guideline for treating chronic pain.

Drug Enforcement Agency

NPAC submitted a written response to the DEA’s quotas of controlled medications.

National Institutes of Health

NPAC submitted a written response to the Office on Women’s Health Research’s request for information on research related to chronic debilitating conditions affecting women.

Center for Medicare and Medicaid Services

NPAC submitted a written comment on CMS’ proposed rule, Revisions to Payment Policies under the Medicare Physician Fee, regarding codes and payment for chronic pain management.

Food and Drug Administration

NPAC submitted a written comment to the FDA’s request for comment on Morphine Milligram Equivalents (MMEs).

Centers for Disease Control and Prevention

NPAC provided oral testimony and a written comment to the Board of Scientific Advisors to the CDC.

Agency for Healthcare Research and Quality

NPAC submitted the following comment to the Agency for Healthcare Research and Quality (AHRQ) regarding its draft report on Integrated Pain Management Programs.

Food and Drug Administration

NPAC submitted the following testimony to the Food and Drug Administration.

CARA 2.0/3.0

NPAC successfully fought a federal bill that would have imposed arbitrary and harmful three-day limits on opioid prescribing nationwide.

RI Intractable Pain Bill

NPAC supported an intractable pain bill in Rhode Island.

FDA Comments

NPAC commented on the Food and Drug Administration’s request for comment on how best to evaluate its REMS education program for prescribing opioid analgesics.

Minnesota Comments

We responded to The Minnesota Department of Human Services (DHS) on its proposed revisions to Section V of the Minnesota Opioid Prescribing Guidelines, Tapering Opioid Therapy.

NQF Comments

We wrote to urge NQF to consider integrating into its quality metrics: patient metrics of quality and success; metrics that measure patient outcomes; and metrics that measure continuity of care.

NQF thanked us for our original comment and asked us to provide additional feedback:

Oregon Comments

We responded to the Oregon Health Authority’s revision of its recommendations not to cover opioids for Medicaid patients in 170 conditions of the back, neck and spine.

DEA Comments

We responded to the Drug Enforcement Agency (DEA)’s call to further cut the medical supply of schedule I and II controlled substances during a global pandemic, and at a time when hospitals have reported experiencing shortages of necessary medication.

NICE Guideline Comments

We submitted extensive comments on a proposed guideline in the United Kingdom, the National Institute for Health and Care Excellence (NICE) Guideline on Chronic Pain: Assessment and Management, which uses new categories of “primary chronic pain” and “secondary chronic pain” to make recommendations for prescribing.

< BACK TO ADVOCACY